Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Fu, Rongzhan; Wu, Hongyan; Yuan, Kai; Zhang, Kun

doi:10.5372/1905-7415.0604.092

Abstract

Background: Phosphorylation of proline-rich Akt substrate of 40 kilodaltons at Thr246 (p-PRAS40^Thr246) is a novel identified specific and stable biomarker for predicting phosphatidylinositol 3-kinase (PI3K) pathway activation and AKT inhibitor sensitivity.

Objectives: We investigated the expression of p-PRAS40^Thr246 in breast cancer, and their clinicopathological characteristics and prognostic significance.

Methods: The expression of p-PRAS40^Thr246 was detected by immunohistochemistry in 117 invasive breast cancer tumors.

Results: p-PRAS40^Thr246 was positive in 62 (53.0%) of 117 patients. p-PRAS40^Thr246 expression was significantly associated with late tumor stages and shorter survival, but not with other clincopathological characteristics. Furthermore, p-PRAS40^Thr246 was also an independent prognostic factor for invasive breast cancers.

Conclusion: High prevalence of p-PRAS40^Thr246 overexpression and its clinical significance in breast cancer suggests that this subgroup might benefit from PI3K inhibitors. We proposed that the detection of p-PRAS40Thr246 in breast cancer tissues should be included in the future clinical practice to develop patient-tailored treatments.

References

1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, el al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.10.1126/science.1096502
Search in Google Scholar Back to article
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9:550-62.10.1038/nrc2664
Open DOI Search in Google Scholar Back to article
3. Hernandez-Aya LF, Gonzalez-Angulo AM.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16:404-14.10.1634/theoncologist.2010-0402
Open DOI Search in Google Scholar Back to article
4. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010; 2:43ra55.10.1126/scitranslmed.3001065
Open DOI Search in Google Scholar Back to article
5. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009; 14:55-66.10.1007/s10911-009-9116-x
Open DOI Search in Google Scholar Back to article
6. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska- Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009; 8:21-6.10.4161/cbt.8.1.7209
Search in Google Scholar Back to article
7. Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat. 2010; 124:1-11.10.1007/s10549-010-1108-4
Search in Google Scholar Back to article
8. Moulder SL.Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer. 2010; 10 Suppl 3: S66-71.10.3816/CBC.2010.s.014
Open DOI Search in Google Scholar Back to article

Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Abstract

Paradigm

My account